Evidence map›Paper›PMID 20831921›Full record

ReviewDisease-a-month : DM2010

Alzheimer disease.

Rudy J Castellani, Raj K Rolston, Mark A Smith

Abstract readReview
In one paragraph

Review in Disease-a-month : DM, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 221 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
221citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

221 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. From adolescence to Alzheimer's: a neurodevelopmental lifespan model of cognitive vulnerability.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
  7. Review
  8. Mechanisms of damage and therapies for cardiac amyloidosis: a role for inflammation?Clinical research in cardiology : official journal of the German Cardiac Society · 2026
    Review
  9. Usefulness ofInternational journal of molecular sciences · 2026
    Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

161 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rudy J Castellani
Raj K Rolston
Mark A Smith

Funding

Role of Cell Cycle in NeurodegenerationR01AG028679 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI LEE, HYOUNG-GON · 2008 to 2012
$1.6M
Amyloid-beta: The Alternate HypothesisR01AG026151 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI SMITH, MARK A · 2005 to 2007
$741k
Cell Cycle Inhibitors in Alzheimer DiseaseR21AG031364 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI SMITH, MARK A · 2007 to 2008
$357k
NIA NIH HHS AG026151NIA NIH HHS AG028679NIA NIH HHS AG031364NIA NIH HHS R01 AG026151NIA NIH HHS R01 AG028679NIA NIH HHS R21 AG031364
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAged, 80 and overAge DistributionAlzheimer DiseaseAmyloid beta-PeptidesAniline CompoundsAntioxidantsBiomarkersBrainCerebral Amyloid AngiopathyCholinergic AgentsDementiaDiagnosis, DifferentialDiet, MediterraneanEstrogen Replacement TherapyGlobal Health2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazoleAmyloid beta-PeptidesAniline CompoundsAntioxidantsBiomarkersCholinergic AgentsNerve Growth Factorstau ProteinsThiazoles

Identifiers

PMID20831921
PMCPMC2941917

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.